<DOC>
	<DOCNO>NCT02760602</DOCNO>
	<brief_summary>The main purpose study investigate safety efficacy study drug solanezumab participant prodromal Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>A Study Solanezumab ( LY2062430 ) Participants With Prodromal Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Has diagnosis study investigator clinical syndrome cognitive impairment consistent prodromal AD per International Working Group ( IWG ) diagnostic criterion MCI due AD per National Institute AgingAlzheimer 's Association ( NIAAA ) diagnostic criterion . Scores 1728 MoCA screen . Scores &lt; 27 free recall cutoff score FCSRT ( Picture version ) screening . Scores â‰¤4 Modified Hachinski Ischemia Scale ( MHIS ) . Scores &gt; 0 FAQ . Has florbetapir PET scan CSF result screen consistent presence amyloid pathology . Has MRI computerize tomography ( CT ) brain within previous 2 year show pathology would inconsistent diagnosis AD . Has know allergy humanize monoclonal antibody . Has ongoing clinically significant laboratory abnormality , determine investigator . Has screen MRI result show &gt; 4 amyloid relate image abnormality H ( ARIAH ) microhemorrhages presence ARIAE . Has contraindication MRI study , include claustrophobia , presence metal ( ferromagnetic ) implant , cardiac pacemaker compatible MRI . Has receive treatment stable dose achetylcholinesterase ( AChEI ) inhibitor memantine le 2 month randomization . ( If participant recently stop AChEIs and/or memantine , must discontinue treatment least 2 month randomization . )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>anti-amyloid</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>